Literature DB >> 26770484

The clinical characteristics of 80 cases of acquired immunodeficiency syndrome-associated Kaposi's sarcoma in Xinjiang Autonomous Region and the effect of different treatments on the prognosis.

Tongtong Yang1, Li He2, Xuefeng Wan3, Wubuli Maimaitiaili2, Yuxia Song1, Yuexin Zhang2, Xiaobo Lu2.   

Abstract

To analyze the clinical features of AIDS-related Kaposi's sarcoma (AIDS-KS) patients in Xinjiang Autonomous Region and the impact of CD4 (+)T lymphocyte count, highly active antiretroviral therapy (HAART) and systemic chemotherapy on the prognosis. The clinical information of 80 AIDS-KS patients admitted in Sixth People's Hospital of Xinjiang Autonomous Region from January 2008 to August 2014 was retrospectively reviewed. Population characteristics, extent of lesions, KS progress, CD4 (+)T lymphocyte count, combined opportunistic infections, treatment and prognosis of these patients were analyzed. The 80 patients were divided into five groups according to treatment methods, including HAART, HAART + chemotherapy, chemotherapy + HAART, chemotherapy, and untreated groups. The efficacy and prognosis of the five groups were compared. Among the 80 patients, 74 (92.50%) patients were Uygur. The average age was 39.5±9.9 years and male-to-female ratio was 3:1. The median of baseline CD4 (+)T lymphocyte count was 152.5 cells/μL and the interquartile was 233.25 cells/μL. CD4 (+)T lymphocyte counts were significantly increased after treatment in HAART, HAART + chemotherapy, and chemotherapy + HAART groups (P < 0.05). CD4 (+)T lymphocyte count in chemotherapy groups was significantly reduced after treatment (P < 0.05). The untreated group had the highest mortality rate (33.3%). In HAART group, KS-associated immune reconstitution inflammatory response syndrome (KS-IRIS) appeared in 45.5% cases and 2 death cases were caused by KS-IRIS. In Xinjiang Autonomous Region, the incidence of AIDS-KS is high in young Uygur male people. HAART followed by chemotherapy has ideal efficacy, reduces the incidence of KS-IRIS and improves the prognosis.

Entities:  

Keywords:  Kaposi’s sarcoma; acquired immunodeficiency syndrome; prognosis

Year:  2015        PMID: 26770484      PMCID: PMC4694384     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  13 in total

1.  Immune reconstitution inflammatory syndrome of Kaposi's sarcoma in an HIV-infected patient.

Authors:  Ching-Lan Lu; Sui-Yuan Chang; Yu-Tzu Tseng; Bing-Ru Wu; Wen-Chun Liu; Chia-Yin Hsieh; Pei-Ying Wu; Hsin-Yun Sun; Chien-Ching Hung
Journal:  J Microbiol Immunol Infect       Date:  2012-04-12       Impact factor: 4.399

2.  Risk factors for Kaposi's sarcoma among HIV-positive individuals in a case control study in Cameroon.

Authors:  Kristen Stolka; Paul Ndom; Jennifer Hemingway-Foday; Jeniffer Iriondo-Perez; Wendell Miley; Nazzarena Labo; Jennifer Stella; Mahamat Abassora; Godfrey Woelk; Robin Ryder; Denise Whitby; Jennifer S Smith
Journal:  Cancer Epidemiol       Date:  2014-03-13       Impact factor: 2.984

3.  [Clinical manifestation of HIV infection and AIDS in otorhinolaryngology head and neck surgery].

Authors:  Yong-qiang Li; Jian Huang; Wen-shan Zhang
Journal:  Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi       Date:  2011-03

4.  Radiotherapy in the management of epidemic Kaposi's sarcoma: a retrospective study of 643 cases.

Authors:  Y M Kirova; E Belembaogo; H Frikha; E Haddad; E Calitchi; E Levy; P Piedbois; J P Le Bourgeois
Journal:  Radiother Oncol       Date:  1998-01       Impact factor: 6.280

5.  A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy-naive patients with HIV-associated Kaposi sarcoma in South Africa.

Authors:  Anisa Mosam; Fahmida Shaik; Thomas S Uldrick; Tonya Esterhuizen; Gerald H Friedland; David T Scadden; Jamila Aboobaker; Hoosen M Coovadia
Journal:  J Acquir Immune Defic Syndr       Date:  2012-06-01       Impact factor: 3.731

Review 6.  [Opportunistic infections in HIV/AIDS].

Authors:  Akira Yasuoka
Journal:  Nihon Rinsho       Date:  2010-03

Review 7.  The epidemiologic, pathologic, and clinical features of AIDS-associated pulmonary Kaposi's sarcoma.

Authors:  D M Aboulafia
Journal:  Chest       Date:  2000-04       Impact factor: 9.410

Review 8.  Recrudescent Kaposi's sarcoma after initiation of HAART: a manifestation of immune reconstitution syndrome.

Authors:  Rom S Leidner; David M Aboulafia
Journal:  AIDS Patient Care STDS       Date:  2005-10       Impact factor: 5.078

9.  Post-transplant Kaposi sarcoma originates from the seeding of donor-derived progenitors.

Authors:  Patrizia Barozzi; Mario Luppi; Fabio Facchetti; Cristina Mecucci; Milena Alù; Ronit Sarid; Valeria Rasini; Luisa Ravazzini; Elisa Rossi; Silvana Festa; Barbara Crescenzi; Dana G Wolf; Thomas F Schulz; Giuseppe Torelli
Journal:  Nat Med       Date:  2003-04-07       Impact factor: 53.440

10.  Successful treatment of an HIV-positive patient with unmasking Kaposi's sarcoma immune reconstitution inflammatory syndrome.

Authors:  David J Speicher; Marjoree M Sehu; Newell W Johnson; David R Shaw
Journal:  J Clin Virol       Date:  2013-04-08       Impact factor: 3.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.